Emerald Mutual Fund Advisers Trust’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-104,394	Closed	-$7.94M	–	248
2013 Q4	$7.94M	Buy	104,394 +5,968	+6%	+$354K	0.47%	85
2013 Q3	$6.24M	Buy	98,426 +19,940	+25%	+$982K	0.86%	42
2013 Q2	$3.29M	Buy	+78,486	New	+$3.58M	0.56%	73

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's GEVA Position: Q1 2014 in Review

Emerald Mutual Fund Advisers Trust sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2014, closing a stake of 104,394 shares — an estimated $7.94M sold.

Emerald Mutual Fund Advisers Trust first reported a position in GEVA in Q2 2013 and held it in 3 quarters. The position peaked at $7.94M in Q4 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q1 2014.

Emerald Mutual Fund Advisers Trust reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 104,394 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2014, an estimated $7.94M.
Emerald Mutual Fund Advisers Trust first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 3 quarters.
Emerald Mutual Fund Advisers Trust's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $7.94M in Q4 2013.
115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2014.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2014, filed 30 Apr 2014.